[The effect of inhaled nitric oxide on endothelium-derived angiokinetic factors in patients with acute high altitude disease].
OBJECTIVE
To study the effect of inhaled nitrogen monoxidum (NO) on endothelium-derived angiokinetic factors including NO, endothelin (ET), thromboxane B(2) (TXB(2)) and 6-keto-prostaglandin F(1a) (6-Keto-PGF(1a)) in patients with acute high altitude disease.


METHODS
Forty-seven patients with acute high altitude disease were selected and divided into two groups randomly: twenty-three cases as a routine medical treatment group, for which oxygen, aminophylline, dexamethasone and furosemide were used, while 24 cases as a NO treatment group, for which only inhalation of 0.001% NO gas with air balanced in plateau (altitude 3658 m), were given twice daily (AM and PM each for an hour). The level of serum NO, ET, TXB(2) and 6-Keto-PGF(1a) were measured, and the changes of clinical symptoms were scored using the Lake Louise acute high altitude disease scoring.


RESULTS
In the two groups, the level of ET [(78 +/- 8) and (69 +/- 5) ng/L], TXB(2) [(87 +/- 13) and (73 +/- 8) ng/L], ET/NO [(26.7 +/- 1.5) x 10(3) and (21.8 +/- 1.1) x 10(3)], TXB(2)/6-Keto-PGF(1a) (0.84 +/- 0.36 and 0.58 +/- 0.11, clinical symptom score 2.4 +/- 1.6 and 1.8 +/- 1.3) after treatment were decreased significantly as compared to the levels of ET [(83 +/- 8) and (84 +/- 4) ng/L], TXB(2) [(102 +/- 16) and (103 +/- 13) ng/L], ET/NO [(35.0 +/- 2.7) x 10(3) and (36.3 +/- 3.1) x 10(3)], TXB(2)/6-Keto-PGF(1a) (1.28 +/- 0.38 and 1.24 +/- 0.28), clinical symptom score (4.4 +/- 2.3 and 4.4 +/- 2.0) before treatment. After treatment, the level of NO [(2880 +/- 537) and (3167 +/- 192) microg/L] and 6-Keto-PGF(1a) [(122 +/- 46) and (128 +/- 15) ng/L] were significantly higher than the level of NO [(2372 +/- 144) and (2313 +/- 188) microg/L] and 6-Keto-PGF(1a) [(86 +/- 28) and (86 +/- 13) ng/L] before treatment.


CONCLUSIONS
Inhaled NO is an effective treatment for high altitude disease in plateau, probably by modulating the angiokinetic factors.
Zheng
Bi-hai
BH
Laboratory of the Center of High Altitude Medicine PLA, the Military General Hospital of Tibet, Lasa 850007, China.
Li
Su-zhi
SZ
He
Yi
Y
Wang
Hong-bin
HB
Li
Shang-shi
SS
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000280:Administration, Inhalation; D000293:Adolescent; D000532:Altitude Sickness / Q000378:metabolism*; D016232:Endothelins / Q000097:blood; D004727:Endothelium / Q000378:metabolism*; D006801:Humans; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D055815:Young Adult
D016232:Endothelins; D009569:Nitric Oxide; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha